–
NETWORK
This consortium has a vision to produce much needed translational researchers.
To achieve this, six leading academic institutions, all with a fully equipped PET centre on site, and two strategically chosen non-academic institutions have been brought together as beneficiaries in this ITN.
–
LOCATIONS of Beneficiaries
1. Loughborough University
2. VU University Medical Center Amsterdam
6. European Institute for Molecular Imaging
7. Imanova Ltd
Partners
Univeristy College London
–
BENEFICIARIES
–
BENEFICIARIES
–
UNIVERSITY OF ABERDEEN
Beneficiary 01.06.16 to 31.12.18
Partner since 01.01.19
Founded in 1495, Aberdeen is the fifth oldest University in the UK. It is ranked within the world top 140 in the recent QS global league table. Aberdeen is a broad based, research intensive University. The University has over 14,000 matriculated students and 3,600 staff representing 120 nationalities. The integrative centres within the Institute of Medical Sciences offer state of the art imaging infrastructure including preclinical and clinical MRI, preclinical and clinical PET/CT, cyclotron and radiochemistry laboratories.
Aberdeen city itself has a population approaching 230,000, big enough to provide all the advantages of city life, yet compact enough to enjoy the more intimate atmosphere usually associated with small towns. Royal Deeside and the Cairngorms National Park are within Easy access of the city ( www.VisitScotland.com).
–
VUMC AMSTERDAM
The Department of Radiology & Nuclear Medicine of the VU University Medical Centre (VUmc; www.vumc.nl), part of the Stichting VU, in Amsterdam is dedicated to both development and application of molecular imaging procedures with an emphasis on PET. This mission is reflected in the multi-disciplinary character of the department, which consists of radiochemists, radiopharmacists, biologists, physicists, computer scientists and nuclear medicine physicians. The department is equipped with two PET/CT scanners, one PET/MRI scanner, and preclinical PET/CT and PET/MRI scanners enabling studies in humans and experimental animals with high spatial resolution. For radiochemistry purposes the department has access to five on-site cyclotrons and, apart from the usual radiochemistry facilities, is equipped with a fully GMP compliant hotlab with 12 hotcells.
–
VRIJE UNIVERSITEIT BRUSSEL
The Vrije Universiteit Brussel is the largest Dutch-speaking employer in the Brussels Region, offering a quality education to more than 9000 students. A basic principle, incorporated in the university statutes of the Vrije Universiteit Brussel, is that the institution must be managed according to the model of democracy. In concrete terms, this means that all echelons, from professors and assistants over researchers, students, administrative staff and technical personnel, are represented on all its governing bodies. At the In Vivo Cellular and Molecular Imaging (ICMI) Lab of the Vrije Universiteit Brussel (VUB), we have centralised multiple small animal imaging modalities including MicroSPECT, MicroPET, MRI, Optical imaging, MicroCT and Ultrasound together with a unit for probe development and a vivarium for the housing of animals in one laboratory.
–
UNIVERSITY OF BERGEN
The University of Bergen (UiB) is an internationally recognised research university. Academic diversity and high quality are fundamental. There are seven faculties at UiB and a total of 14,800 students and 3,600 staff at the university, with PhD candidates paid staff employees. Department of Chemistry has a wide range of in-house modern scientific instrumentation, including NMR spectrometers: 600 MHz for high resolution liquid phase, 500 MHz for solid state, diffusion measurements and high resolution NMR, and a 400 MHz instrument for routine analysis in liquid phase· X-ray diffraction, dedicated single-crystal as well as powder instrument· IR, NIR and Raman spectrometers· Mass Spectrometry high resolution hyphenated system· Computer resources designated for molecular modelling.
–
ASOCIACIÓN CIC BIOMAGUNE
The Center for Cooperative Research in Biomaterials- CIC biomaGUNE, located in San Sebastián (Spain), was officially opened in December 2006. CIC biomaGUNE is a non-profit research organisation created to promote scientific research and technological innovation at the highest levels in the Basque Country following the BioBasque policy, to create a new business sector based on biosciences. The Molecular Imaging Facility is a technological platform of high relevance at the European level, in preclinical imaging. It empowers the research capacity at CIC biomaGUNE and provides high expertise service to research centres, hospitals and companies.
–
WESTFAELISCHE WILHELMS-UNIVERSITAET MUENSTER
In 2007, the European Institute for Molecular Imaging (EIMI) was founded by a public-private-partnership between the University and Siemens Medical Solutions. EIMI is a central academic institution of the University of Münster (WWU) working in the fields of developing, validating and applying molecular imaging technologies. EIMI focuses on the development of new molecular imaging approaches to study disease-specific molecular alterations in the major disease areas (cardiovascular disease, oncology, inflammation, neurodegeneration). The most important applications comprise the development of new radiotracers (targeting MMPs, TSPO), imaging studies in mouse model systems (AD, PD), which can be translated into clinical application to serve imaging-guided patient-tailored diagnosis and treatment.
–
Invicro (previously Imanova)
Imanova has world-leading expertise in imaging sciences and their application to the understanding of disease and translational drug development. An innovative joint venture, Imanova’s shareholders are the UK’s Medical Research Council and three world-class London Universities: Imperial College London, King’s College London and University College London. Invicro’s medical imaging capabilities, experience and expertise span several therapeutic areas. Our academic expertise and extensive links with clinicians and scientists in our shareholder institutions provide unrivalled capabilities to facilitate drug development.
–
ASTRAZENECA PLC
AstraZeneca is a global, science-led biopharmaceutical business striving to push the boundaries of science to deliver life-changing medicines. The company has a global workforce of around 61,500 people in more than 100 countries. AstraZeneca is dedicated to building an inclusive, open and trusting organisation that embraces the skills, knowledge and unique abilities of employees. At AstraZeneca, diversity and human rights are prioritised, ensuring everyone has the opportunity to work in a healthy and safe environment.